Loading
VT
Verve Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 15 May 2024.
Verve Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Verve Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Verve Therapeutics, Inc. has had no insider filing for more than a year; the last one goes back to 28 July 2025.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
86
Thresholds
n/a
Buy Volume
€18M
9 ops. · all time
Sell Volume
€10M
19 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
Net income-US$171.1M
Last declaration on 28 July 2025
Declarations86 total
6,108,442 sharesCommon StockSEC:0001415889-25-020384:0
6,108,442 sharesCommon StockSEC:0000950170-25-099263:0
13,280 sharesCommon StockSEC:0000950170-25-099262:0
17,420 sharesCommon StockSEC:0000950170-25-099261:0
348,431 sharesCommon StockSEC:0000950170-25-099260:0
6,952 sharesCommon StockSEC:0000950170-25-099259:0
428,326 sharesCommon StockSEC:0000950170-25-099258:0
16,405 sharesCommon StockSEC:0000950170-25-099255:0
348,828 sharesCommon StockSEC:0000950170-25-099254:0
9,315 sharesCommon StockSEC:0000950170-25-050562:0
8,815 sharesCommon StockSEC:0000950170-25-050560:0
11,250 sharesCommon StockSEC:0000950170-25-050559:0
7,340 sharesCommon StockSEC:0000950170-25-050558:0
33,000 sharesCommon StockSEC:0000950170-25-050563:0
9,000 sharesCommon StockSEC:0000950170-25-050561:0
30,000 shares0Common StockSEC:0000950170-24-133290:0
1,875 sharesCommon StockSEC:0000950170-24-132799:0
30,000 shares@ US$2.8710.1% of flowCommon StockSEC:0000950170-24-080012:0
76,000 shares@ US$6.2659.6% of flowCommon StockSEC:0000950170-24-060613:0
Canonical exit: 12 Aug 2024 (T+90)
3,315 sharesCommon StockSEC:0000950170-24-041237:0
1,800,000 shares@ US$10.00100.0% of flowCommon StockSEC:0000950170-23-068199:0
Canonical exit: 29 Feb 2024 (T+90)
1,875 sharesCommon StockSEC:0000950170-23-067358:0
36,000 shares@ US$2.873.2% of flowCommon StockSEC:0001209191-22-061697:0
865 shares@ US$22.950.6% of flowCommon StockSEC:0001209191-22-059438:0
1,875 sharesCommon StockSEC:0001209191-22-059211:0
25 of 86 declarations
About Verve Therapeutics, Inc.
Verve Therapeutics, Inc. is a U.S.-based biotechnology company listed on the Nasdaq stock market in the United States under the ticker VERV. The company was founded in 2018 in Boston by pioneers in cardiology, gene editing, and drug development, with a focused mission: to change the treatment paradigm for atherosclerotic cardiovascular disease by developing one-time, in vivo gene-editing medicines rather than chronic therapies. Its headquarters are in Boston, placing it at the center of the U.S. biotech ecosystem.
Verve’s business model is built around a genetic-medicine platform aimed at validated cardiovascular targets. Its lead program, VERVE-102, targets PCSK9, a well-established driver of LDL cholesterol biology and cardiovascular risk. The program is designed to deliver durable reductions in LDL-C, with potential applications in heterozygous familial hypercholesterolemia and selected patients with premature coronary artery disease. Beyond VERVE-102, the company has also been building a broader pipeline of preclinical and clinical assets focused on pathways linked to cardiovascular risk, which gives it strategic optionality beyond a single product candidate.
Read moreShow less
From a competitive standpoint, Verve occupies a specialized but potentially high-value niche in next-generation cardiometabolic medicine. Its differentiation lies in the ambition to offer a treatment that may be administered once, or very infrequently, in a therapeutic area historically dominated by lifelong chronic medication. That proposition is compelling because adherence remains a major challenge in lipid management and secondary prevention, and a durable gene-editing approach could expand the addressable market if long-term safety and efficacy continue to hold up.
Recent clinical and corporate developments have been material. In 2025, Verve reported encouraging early data for VERVE-102, including a favorable safety profile and dose-dependent reductions in LDL-C and PCSK9 protein. More importantly from a capital-markets perspective, Verve announced in June 2025 a definitive agreement to be acquired by Eli Lilly, and that transaction was completed in July 2025. For investors, this sequence underscored both the strategic value of the platform and the interest of a large pharmaceutical partner in cardiovascular gene editing.
Geographically, Verve is primarily a U.S. company in terms of headquarters, listing, and corporate governance, while its clinical development has included trial activity across multiple countries. Overall, Verve represents a high-science, high-risk biotechnology story in cardiovascular medicine, with recent M&A activity materially changing its public-market profile on Nasdaq in the United States.
